Chondrosarcoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:32:28 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Chondrosarcoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Trabectedin and Low-Dose Radiation Therapy for Adults and Young Adults with Advanced or Metastatic Soft Tissue and Bone Sarcomas https://clinicaltrials.eu/trial/study-of-trabectedin-and-low-dose-radiation-therapy-for-adults-and-young-adults-with-advanced-or-metastatic-soft-tissue-and-bone-sarcomas/ Wed, 29 Apr 2026 14:29:09 +0000 https://clinicaltrials.eu/trial/study-of-trabectedin-and-low-dose-radiation-therapy-for-adults-and-young-adults-with-advanced-or-metastatic-soft-tissue-and-bone-sarcomas/ This clinical trial focuses on patients with advanced/metastatic sarcomas, which are cancers that develop in soft tissues, bones, or appear as small round-cell tumors. The study specifically looks at three types: soft tissue sarcoma, bone tumors (including osteosarcoma and chondrosarcoma), and small round-cell sarcomas (including Ewing’s sarcoma, rhabdomyosarcoma, and other related tumors).

The study combines two types of treatment: a medication called trabectedin (given through an intravenous infusion) and low-dose radiation therapy. Trabectedin is administered as a solution that is prepared from a powder and given through a special tube placed in a vein. The dose used in this study is 1.5 milligrams per square meter of body surface.

The main goal of this research is to determine how well tumors respond to this combination treatment, particularly in areas that receive radiation therapy. Throughout the study, researchers will monitor changes in tumor size, track how long the treatment remains effective, and assess its effects on pain levels and overall well-being. They will also carefully watch for any side effects that may occur during treatment.

]]> Study of ivosidenib in adults with advanced or metastatic chondrosarcoma with IDH1 mutation who are untreated or have had one prior treatment https://clinicaltrials.eu/trial/study-of-ivosidenib-for-adults-with-advanced-or-metastatic-chondrosarcoma-with-idh1-mutation-untreated-or-previously-treated-with-one-systemic-therapy/ Wed, 29 Apr 2026 14:28:39 +0000 https://clinicaltrials.eu/trial/study-of-ivosidenib-for-adults-with-advanced-or-metastatic-chondrosarcoma-with-idh1-mutation-untreated-or-previously-treated-with-one-systemic-therapy/ This study focuses on conventional chondrosarcoma, a type of bone cancer that has spread locally or to other parts of the body (locally advanced or metastatic) and contains a specific genetic change called an IDH1 mutation. The study will test a medication called ivosidenib (also known as AG-120/S95031), which is given as film-coated tablets taken by mouth.

The purpose of this research is to determine how well ivosidenib works in treating patients with Grade 1 and Grade 2 chondrosarcoma. The study will compare ivosidenib to a placebo in patients who have either not received any previous systemic treatment or have had one prior treatment for their cancer. Participants will be randomly assigned to receive either ivosidenib tablets or matching placebo tablets.

During the study, participants will take the study medication daily. The treatment may continue for up to 24 months. Throughout the study, doctors will monitor the participants’ health and perform regular assessments to check how their cancer responds to the treatment. The study will measure how long participants live without their cancer getting worse, along with other factors such as overall survival and quality of life.

]]> Study on Trabectedin for Adults and Young Adults with Advanced Mesenchymal Chondrosarcoma https://clinicaltrials.eu/trial/study-on-trabectedin-for-adults-and-young-adults-with-advanced-mesenchymal-chondrosarcoma/ Wed, 29 Apr 2026 14:27:49 +0000 https://clinicaltrials.eu/trial/study-on-trabectedin-for-adults-and-young-adults-with-advanced-mesenchymal-chondrosarcoma/ This clinical trial is focused on studying a rare type of cancer called mesenchymal chondrosarcoma, which can occur in both bones and soft tissues. The study is specifically looking at cases that are positive for a genetic marker known as HEY1-NCOA2. The treatment being tested in this study is a medication called trabectedin, which is also known by the code name Ecteinascidin 743. Trabectedin is given as a solution through an intravenous infusion, meaning it is administered directly into the bloodstream through a vein.

The purpose of the study is to explore how effective trabectedin is in treating patients who have already received other types of chemotherapy, specifically those that include a group of drugs called anthracyclines. The study will involve patients who are 16 years or older and have advanced or spreading forms of mesenchymal chondrosarcoma. Participants will receive trabectedin and their response to the treatment will be monitored over time. The study aims to understand how well the tumors respond to the treatment and to gather information on the overall survival and progression-free survival of the patients.

Throughout the study, researchers will also look at the safety of trabectedin and explore the genetic and molecular characteristics of tumors that respond to the treatment compared to those that do not. This includes analyzing patterns in the tumor’s genetic material and evaluating the potential of using a technique called liquid biopsy, which involves testing blood samples to detect the presence of the HEY1-NCOA2 fusion, to predict how well a patient might respond to the treatment. The study is expected to continue until 2027, providing valuable insights into the treatment of this rare cancer type.

]]> Study of INBRX-109 (ozekibart) compared to placebo in adults with unresectable or metastatic chondrosarcoma – a rare bone cancer https://clinicaltrials.eu/trial/study-of-inbrx-109-for-adults-with-unresectable-or-metastatic-conventional-chondrosarcoma/ Wed, 29 Apr 2026 14:22:53 +0000 https://clinicaltrials.eu/trial/study-of-inbrx-109-for-adults-with-unresectable-or-metastatic-conventional-chondrosarcoma/ This study focuses on patients with conventional chondrosarcoma, a type of bone and joint cancer that cannot be surgically removed (unresectable) or has spread to other parts of the body (metastatic). The main treatment being tested is INBRX-109 (also known as ozekibart), which is given through an intravenous infusion. The study will compare this medication to a placebo to determine if it is effective in treating this type of cancer.

The study aims to evaluate how well INBRX-109 works in preventing cancer progression compared to placebo. Participants will receive either INBRX-109 or placebo through an intravenous infusion. Additional medications that may be given during treatment include glucose solution, acetylcysteine, dexamethasone, and diphenhydramine to manage potential side effects of the treatment.

During the study, patients will receive treatment for up to 150 days. The treatment involves regular intravenous infusions of either INBRX-109 or placebo. Doctors will monitor patients’ health status and perform regular imaging tests to check how the cancer responds to treatment. The study will track how long patients live without their cancer getting worse and measure overall survival.

]]>